Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer

被引：0
|
作者：
O'Malley, David M.
Monk, Bradley J.
Lim, Myong Cheol
Pradera, Jose Fuentes
Buscema, Joseph
Wilson, Michelle K.
De Vivo, Rocco
Herzog, Thomas J.
Zagouri, Flora
Oza, Amit M.
Mikheeva, Olga N.
Diaz, John Paul
Lisyanskaya, Alla Sergeevna
Morris, Robert
Bruchim, Ilan
Craib, Marcia
Connor, Christy
Shih, Danny
Fujiwara, Keiichi
Kristeleit, Rebecca
机构：
[1] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH USA
[2] Creighton Univ, Univ Arizona, GOG Fdn, Coll Med,Sch Med, Phoenix, AZ USA
[3] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea
[4] Hosp Univ Virgen Valme, Seville, Spain
[5] Arizona Oncol Associates, Tucson, AZ USA
[6] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand
[7] Osped San Bortolo, Dept Med Oncol, Vicenza, Italy
[8] Univ Cincinnati, Cincinnati, OH USA
[9] Alexandra Hosp, Dept Clin Therapeut, Athens, Greece
[10] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[11] Ltd Liabil Co MedPomosch, St Petersburg, Russia
[12] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[13] St Petersburg State Budget Healthcare Inst, City Clin Oncol Dispensary, St Petersburg, Russia
[14] Wayne State Univ, Karmanos Canc Inst, Div Gynecol Oncol, Dept Oncol,Sch Med, Detroit, MI USA
[15] Rappaport Fac Med, Hillel Yaffe Med Ctr, Hadera, Israel
[16] Pharma&, Stat Programming, New York, NY USA
[17] Pharma&, Clin Operat, New York, NY USA
[18] Saitama Med Univ Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan
[19] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5554
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
  • [22] Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
    Oza, Amit M.
    Matulonis, Ursula A.
    Malander, Susanne
    Hudgens, Stacie
    Sehouli, Jalid
    del Campo, Josep M.
    Berton-Rigaud, Dominique
    Banerjee, Susana
    Scambia, Giovanni
    Berek, Jonathan S.
    Lund, Bente
    Tinker, Anna V.
    Hilpert, Felix
    Palacio Vazquez, Isabel
    D'Hondt, Veronique
    Benigno, Benedict
    Provencher, Diane
    Buscema, Joseph
    Agarwal, Shefali
    Mirza, Mansoor R.
    LANCET ONCOLOGY, 2018, 19 (08): : 1117 - 1125
  • [23] Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trial
    Wu, X.
    Liu, J.
    Wang, X.
    Wang, J.
    Wang, L.
    Zhu, J.
    Kong, B.
    Fei, J.
    Tang, Y.
    Xia, B.
    Liang, Z.
    Wang, K.
    Lin, Z.
    Huang, Y.
    Zheng, H.
    Lin, A.
    Jiang, K.
    Wang, W.
    Wang, X.
    Lou, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1277 - S1278
  • [24] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Coleman, Robert L.
    Oza, Amit M.
    Lorusso, Domenico
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne, I
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert W.
    Amenedo Gancedo, Margarita
    Fong, Peter C.
    Goh, Jeffrey C.
    O'Malley, David M.
    Armstrong, Deborah K.
    Garcia-Donas, Jesus
    Swisher, Elizabeth M.
    Floquet, Anne
    Konecny, Gottfried E.
    McNeish, lain A.
    Scott, Clare L.
    Cameron, Terri
    Maloney, Lara
    Isaacson, Jeff
    Goble, Sandra
    Grace, Caroline
    Harding, Thomas C.
    Raponi, Mitch
    Sun, James
    Lin, Kevin K.
    Giordano, Heidi
    Ledermann, Jonathan A.
    LANCET, 2017, 390 (10106): : 1949 - 1961
  • [25] Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
    Pothuri, Bhavana
    Han, Sileny
    Chase, Dana M.
    Heitz, Florian
    Burger, Robert A.
    Gaba, Lydia
    Van Le, Linda
    Guerra, Eva
    Bender, David
    Korach, Jacob
    Cloven, Noelle
    Churruca, Cristina
    Follana, Philippe
    DiSilvestro, Paul
    Baurain, Jean-Francois
    Jardon, Kris
    Pisano, Carmela
    Peen, Ulla
    Maenpaa, Johanna
    Gupta, Divya
    Bacque, Emeline
    Li, Yong
    Compton, Natalie
    Antonova, Jenya
    Monk, Bradley J.
    Gonzalez-Martin, Antonio
    GYNECOLOGIC ONCOLOGY, 2024, 184 : 168 - 177
  • [26] DUPILUMAB TREATMENT IN PATIENTS WITH ATOPIC HAND AND FOOT DERMATITIS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Worm, Margitta
    Honari, Golara
    Masuda, Koji
    Schuttelaar, Marie-Louise A.
    Maloney, Jennifer
    Xiao, Jing
    Dubost-Brama, Ariane
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 54
  • [27] Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial
    Simpson, Eric L.
    Silverberg, Jonathan, I
    Worm, Margitta
    Honari, Golara
    Masuda, Koji
    Sygula, Ewa
    Maloney, Jennifer
    Mannent, Leda P.
    Xiao, Jing
    Dubost-Brama, Ariane
    Bansal, Ashish
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [28] Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Simpson, E.
    Silverberg, J.
    Worm, M.
    Honari, G.
    Masuda, K.
    Sygula, E.
    Maloney, J.
    Mannent, L.
    Xiao, J.
    Dubost-Brama, A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S350 - S350
  • [29] Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial
    Monk, B. J.
    Barretina-Ginesta, M. P.
    Pothuri, B.
    Vergote, I.
    Graybill, W.
    Mirza, M. R.
    Mccormicky, C. C.
    Lorusso, D.
    Moore, R. G.
    Freyer, G.
    O'Cearbhaill, R. E.
    Heitz, F.
    O'Malley, D. M.
    Redondo, A.
    Shahin, M. S.
    Vulsteke, C.
    Bradley, W. H.
    Haslund, C. A.
    Chase, D. M.
    Pisano, C.
    Holman, L. L.
    Perez, M. J. Rubio
    Disilvestro, P.
    Gaba, L.
    Herzog, T. J.
    Bruchim, I.
    Compton, N.
    Shtessel, L.
    Malinowska, I. A.
    Gonzalez-Martin, A.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 981 - 992
  • [30] Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Pignata, Sandro
    Bookman, Michael
    Sehouli, Jalid
    Miller, Austin
    Penson, Richard T.
    Taskiran, Cagatay
    Anderson, Charles
    Hietanen, Sakari
    Myers, Tashanna
    Madry, Radoslaw
    Willmott, Lyndsay
    Lortholary, Alain
    Thomes-Pepin, Jessica
    Aghajanian, Carol
    Mccourt, Carolyn
    Stuckey, Ashley
    Wu, Xiaohua
    Nishio, Shin
    Copeland, Larry J.
    He, Yvette
    Molinero, Luciana
    Patel, Sheetal
    Lin, Yvonne G.
    Khor, Victor K.
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2023, 177 : 20 - 31
12345